Key facts
- It has raised $28.0M across 2 recorded rounds; the latest was Early Stage VC ($5.3M) in Aug 2024.
- Notable investors include Endless Frontier Labs, Gates Foundation, Wellcome Trust, Empire State Development, Defense Advanced Research Projects Agency — 6 tracked in total.
- RenBio has filed 2 Form Ds with the SEC since 2021, most recently Sep 2024 ($5.3M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for RenBio
Funding rounds
2 roundsAbout RenBio
Developer of an antibody delivery system designed to revolutionize the state of antibody therapeutics. The company's platform is compatible with any antibody, serves as a true platform technology, and can be used for numerous therapeutic indications, enabling healthcare professionals to overcome current manufacturing and delivery challenges and transform the landscape of antibody treatments.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Employees
- 14
- Website
- renbio.com/
- Ownership
- Privately Held (backing)
RenBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RenBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RenBio in its N-PORT filings yet. We sweep new filings monthly.